Literature DB >> 28967906

EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms.

N Venkatesan1, J F Wong1, K P Tan2,3, H H Chung1, Y H Yau1, E Cukuroglu4, A Allahverdi1, L Nordenskiöld1, J Göke4,5, S Geifman-Shochat1, V C L Lin1, M S Madhusudhan2,6,7, I-H Su1.   

Abstract

Recently, we reported that the histone methyltransferase, EZH2, controls leukocyte migration through interaction with the cytoskeleton remodeling effector, VAV, and direct methylation of the cytoskeletal regulatory protein, Talin. However, it is unclear whether this extranuclear, epigenetic-independent function of EZH2 has a profound impact on the initiation of cellular transformation and metastasis. Here, we show that EZH2 increases Talin1 methylation and cleavage, thereby enhancing adhesion turnover and promoting accelerated tumorigenesis. This transforming capacity is abolished by targeted disruption of EZH2 interaction with VAV. Furthermore, our studies demonstrate that EZH2 in the cytoplasm is closely associated with cancer stem cell properties, and that overexpression of EZH2, a mutant EZH2 lacking its nuclear localization signal (EZH2ΔNLS), or a methyl-mimicking Talin1 mutant substantially promotes JAK2-dependent STAT3 activation and cellular transformation. Taken together, our results suggest a critical role for the VAV interaction-dependent, extranuclear action of EZH2 in neoplastic transformation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28967906     DOI: 10.1038/onc.2017.309

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  81 in total

1.  A complex Polycomb issue: the two faces of EZH2 in cancer.

Authors:  Hanno Hock
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

2.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.

Authors:  Shuet Theng Lee; Zhimei Li; Zhenlong Wu; Meiyee Aau; Peiyong Guan; R K Murthy Karuturi; Yih Cherng Liou; Qiang Yu
Journal:  Mol Cell       Date:  2011-09-02       Impact factor: 17.970

3.  The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin.

Authors:  Merry Gunawan; Nandini Venkatesan; Jia Tong Loh; Jong Fu Wong; Heidi Berger; Wen Hao Neo; Liang Yao Jackson Li; Myint Khun La Win; Yin Hoe Yau; Tiannan Guo; Peter Chi Ee See; Sayuri Yamazaki; Keh Chuang Chin; Alexandre R Gingras; Susana Geifman Shochat; Lai Guan Ng; Siu Kwan Sze; Florent Ginhoux; I-hsin Su
Journal:  Nat Immunol       Date:  2015-03-09       Impact factor: 25.606

Review 4.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

5.  Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2.

Authors:  Lianying Jiao; Xin Liu
Journal:  Science       Date:  2015-10-15       Impact factor: 47.728

6.  The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells.

Authors:  Carmen Citterio; Mauricio Menacho-Márquez; Ramón García-Escudero; Romain M Larive; Olga Barreiro; Francisco Sánchez-Madrid; Jesús M Paramio; Xosé R Bustelo
Journal:  Sci Signal       Date:  2012-10-02       Impact factor: 8.192

Review 7.  The c-myc promoter: still MysterY and challenge.

Authors:  Inken Wierstra; Jürgen Alves
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

8.  EZH2 expands breast stem cells through activation of NOTCH1 signaling.

Authors:  Maria E Gonzalez; Heather M Moore; Xin Li; Kathy A Toy; Wei Huang; Michael S Sabel; Kelley M Kidwell; Celina G Kleer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

Review 9.  Lysine methylation and 'signaling memory'.

Authors:  I-hsin Su; Alexander Tarakhovsky
Journal:  Curr Opin Immunol       Date:  2006-02-07       Impact factor: 7.486

Review 10.  Targeting EZH2 in cancer.

Authors:  Kimberly H Kim; Charles W M Roberts
Journal:  Nat Med       Date:  2016-02       Impact factor: 53.440

View more
  6 in total

Review 1.  The Vav GEF Family: An Evolutionary and Functional Perspective.

Authors:  Sonia Rodríguez-Fdez; Xosé R Bustelo
Journal:  Cells       Date:  2019-05-16       Impact factor: 6.600

2.  Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.

Authors:  Xiaoning Wu; Helen Scott; Sigrid V Carlsson; Daniel D Sjoberg; Lucia Cerundolo; Hans Lilja; Remko Prevo; Guillaume Rieunier; Valentine Macaulay; Geoffrey S Higgins; Clare L Verrill; Alastair D Lamb; Vincent T Cunliffe; Chas Bountra; Freddie C Hamdy; Richard J Bryant
Journal:  Prostate       Date:  2019-05-18       Impact factor: 4.104

3.  Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.

Authors:  Swathi Ramakrishnan; Victoria Granger; Monika Rak; Qiang Hu; Kristopher Attwood; Lanni Aquila; Nithya Krishnan; Rafal Osiecki; Gissou Azabdaftari; Khurshid Guru; Gurkamal Chatta; Geraldine Gueron; Lacey McNally; Joyce Ohm; Jianmin Wang; Anna Woloszynska
Journal:  Cell Death Differ       Date:  2019-01-28       Impact factor: 15.828

4.  EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells.

Authors:  Min Zheng; Ming-Xin Cao; Xiao-Jie Luo; Li Li; Ke Wang; Sha-Sha Wang; Hao-Fan Wang; Ya-Jie Tang; Ya-Ling Tang; Xin-Hua Liang
Journal:  J Cell Mol Med       Date:  2019-07-31       Impact factor: 5.310

5.  Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein.

Authors:  Brajendra K Tripathi; Meghan F Anderman; Disha Bhargava; Luciarita Boccuzzi; Xiaolan Qian; Dunrui Wang; Marian E Durkin; Alex G Papageorge; Fernando J de Miguel; Katerina Politi; Kylie J Walters; James H Doroshow; Douglas R Lowy
Journal:  Nat Commun       Date:  2021-12-03       Impact factor: 14.919

6.  The metabolic addiction of cancer stem cells.

Authors:  Om Saswat Sahoo; Karthikeyan Pethusamy; Tryambak P Srivastava; Joyeeta Talukdar; Mohammed S Alqahtani; Mohamed Abbas; Ruby Dhar; Subhradip Karmakar
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.